Atossa Therapeutics Advances Breast Cancer Treatments Following Key FDA Meeting on (Z)-endoxifen

Atossa Therapeutics Advances Breast Cancer Strategies Following FDA Meeting

Atossa Therapeutics, Inc. continues to forge ahead in the realm of breast cancer treatment and prevention, bolstered by recent discussions with the U.S. Food and Drug Administration (FDA). On November 17, 2025, the company engages in a Type C meeting to explore regulatory strategies for its investigational drug, (Z)-endoxifen. This interaction proves pivotal as the FDA offers insights into potential expedited pathways for the drug across various clinical settings, such as metastatic breast cancer (mBC), neoadjuvant treatment, and strategies for breast cancer risk reduction. Atossa's President and CEO, Steven Quay, emphasizes the significance of this meeting, viewing it as a key milestone that clarifies the routes necessary for accelerating both clinical development and regulatory review processes.

Central to Atossa's ongoing initiatives is the preparation for a dose-ranging study targeting metastatic breast cancer. The company also continues to enroll participants in the Phase 2 EVANGELINE trial, which focuses on neoadjuvant ER+/HER2- breast cancer. Additionally, Atossa is implementing a low-dose strategy aimed at mitigating breast cancer risk associated with mammographic density. The company has submitted an Investigational New Drug (IND) application for its mBC program and plans to file further INDs in 2026, exploring combination strategies that extend beyond monotherapy. This proactive approach highlights Atossa's commitment to broadening treatment options for patients battling breast cancer.

The company’s structured clinical program, as noted by Senior VP of Research and Development, Janet Rea, aims to achieve decisive milestones efficiently. With nearly 800 participants involved in various trials, Atossa is building a robust foundation for (Z)-endoxifen, recognized for its potent capabilities as a Selective Estrogen Receptor Modulator/Degrader (SERM/D). The insights gained from the FDA are expected to facilitate progress toward multiple regulatory endpoints, reinforcing Atossa's ambitious plans and positioning it to make substantial advancements in breast cancer treatment and prevention.

In addition to these clinical developments, Atossa Therapeutics remains focused on cultivating partnerships that could enhance its research capabilities and expedite its pipeline. The company's commitment to innovation in breast cancer therapeutics is evident as it navigates the regulatory landscape with confidence, aiming to deliver effective treatments to patients in need. The ongoing advancements in (Z)-endoxifen development underline Atossa's dedication to addressing unmet medical needs in the oncology space.